MariMed Inc (MRMD)
OTHER OTC:MRMD
Want to see MRMD full AI Analyst Report?
MRMD Stock Chart & Stats
$0.07
<$0.01(0.85%)
At close: 4:00 PM EST
$0.07
<$0.01(0.85%)
Day’s Range― - ―
52-Week Range$0.06 - $0.23
Previous CloseN/A
Volume101.75K
Average Volume (3M)1.40M
Market Cap
$27.95M
Enterprise Value$117.16M
Total Cash (Recent Filing)$7.94M
Total Debt (Recent Filing)$98.14M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding399,266,080
10 Day Avg. Volume1,629,378
30 Day Avg. Volume1,398,937
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.66
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market Cap4.19
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit2.01
Enterprise Value/Ebitda10.88
Forecast
1Y Price Target
$0.25Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$161.35M
Bulls Say, Bears Say
Bulls Say
Wholesale Growth / Multi-state DistributionStrong wholesale growth in Delaware and Illinois indicates scalable B2B distribution and broader market penetration. Durable wholesale momentum diversifies revenue beyond retail, supports higher volumes, and strengthens bargaining power with retailers, reducing reliance on single-store retail performance over the medium term.
Positive Operating Cash Flow And Improving EBITDAConsistent operating cash generation and positive adjusted EBITDA show the business can fund operations and modest growth from operations rather than financing. Over 2–6 months this supports reinvestment, license renewals and measured expansion while partially offsetting GAAP losses and enabling deleveraging choices.
Brand Strength And Customer LoyaltyLeading brands and a large, sticky loyalty base drive recurring sales and higher wallet share. High digital adoption and member-driven revenue improve customer lifetime value and lower marketing intensity. Brand and loyalty durability supports steady retail volumes amid competitive churn.
Bears Say
Elevated Leverage And Weak Equity BaseVery high leverage severely limits financial flexibility, increases refinancing risk, and constrains the company's ability to fund capex or M&A without dilutive or expensive financing. Over months this raises default and covenant sensitivity if cash flow weakens or rates move unfavorably.
Persistent GAAP Losses And Margin PressureSustained margin compression and ongoing GAAP losses indicate structural cost or pricing pressures that could limit long-term profitability. Even with positive adjusted EBITDA, the gap to GAAP profitability reduces retained earnings, hinders equity rebuilding, and weakens resilience to market downturns.
Category Price Compression And Store-level CompetitionOngoing price deflation and intensifying local competition erode average order values and margins at store level. Structural category commoditization forces higher marketing and loyalty spend to defend share, raising operating costs and making margin recovery harder even as revenue growth continues.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was $0.06 and its highest was $0.23 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is $27.95M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is Aug 12, 2026 which is in 52 days.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on May 13, 2026. The company reported -$0.008 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.002.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Undervalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 399,266,080 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of -$0.008 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MariMed Inc
MariMed Inc. operates in the cannabis industry, specializing in the cultivation, production, and sale of both medicinal and adult-use cannabis items throughout the United States and internationally. The company's diverse product portfolio includes cannabis flowers and concentrates marketed under the Nature's Heritage brand. It also offers infused goods such as chewable tablets and powdered drink mixes under the Kalm Fusion label, natural fruit chews known as Betty's Eddies, and a line of baked treats like brownies and cookies available through Bubby's Baked. Furthermore, MariMed develops cannabidiol (CBD) products under the Florance brand. Beyond its own offerings, the company licenses its various brands and product formulations to others and leases facilities designed for cannabis operations. MariMed Inc., founded in 2011, is based in Norwood, Massachusetts.
MRMD Company Deck
MRMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic tone: the company delivered year-over-year revenue growth, positive adjusted EBITDA, stable gross margins above 40%, strong wholesale momentum in Delaware and Illinois, and robust loyalty/digital adoption—offset by expected seasonal retail softness, sequential declines in revenue and EBITDA, ongoing price compression in several markets, a continued GAAP net loss and a modest decline in cash. Management emphasized brand strength, operational discipline, and opportunities from medical rescheduling and state-level expansion (Massachusetts cap increase, Ohio store opening, licensing activity in NY/PA/Maine) while acknowledging near-term headwinds.View all MRMD earnings summariesMRMD Stock 12 Month Forecast
Average Price Target
$0.25
▲(257.14% Upside)
Technical Analysis
Ownership Overview
10.74% Insiders
0.18% Other Institutional Investors
89.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---